SG Americas Securities LLC Has $17.27 Million Stake in IQVIA Holdings Inc. $IQV

SG Americas Securities LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 101.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,280 shares of the medical research company’s stock after purchasing an additional 51,074 shares during the quarter. SG Americas Securities LLC owned about 0.06% of IQVIA worth $17,272,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of IQV. Brighton Jones LLC increased its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares during the period. Empowered Funds LLC lifted its stake in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after acquiring an additional 4,915 shares during the period. Sivia Capital Partners LLC bought a new position in IQVIA in the second quarter valued at about $514,000. First Trust Advisors LP increased its position in IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after purchasing an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC raised its holdings in IQVIA by 5.4% during the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after purchasing an additional 1,155 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.4%

IQV opened at $186.30 on Friday. The firm’s fifty day moving average is $174.17 and its two-hundred day moving average is $190.06. The firm has a market cap of $31.09 billion, a PE ratio of 23.09, a price-to-earnings-growth ratio of 1.59 and a beta of 1.21. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its board has approved a share buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on IQV shares. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. HSBC set a $210.00 price objective on shares of IQVIA in a report on Wednesday, June 3rd. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Finally, Evercore reiterated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.